<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361828</url>
  </required_header>
  <id_info>
    <org_study_id>Beva-ERG-VEP</org_study_id>
    <nct_id>NCT01361828</nct_id>
  </id_info>
  <brief_title>Optic Nerve and Retinal Functions With Bevacizumab</brief_title>
  <official_title>Electrophysiological Assessment of Optic Nerve and Retinal Functions Following Intravitreal Injection of Bevacizumab (Avastin).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the possible affection of optic nerve and retinal
      functions following intravitreal bevacizumab injection in human eyes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the retinal and optic nerve functions of bevacizumab when injected intravitreal
      in human eyes using electrophysiological tests; Electroretinogram (ERG) and Visual Evoked
      Potentials (VEP). Forty five eyes of 45 patients with choroidal neovascular membrane (CNV)
      who were prepared for intravitreal injections of 1.25mg bevacizumab underwent baseline ERG
      and VEP in both eyes before, and at 1 and 4 weeks after the intravitreal injections.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Evoked Potential and Electroretinogram</measure>
    <time_frame>4 weeks</time_frame>
    <description>VEP and ERG baseline and at 1 and 4 weeks post intravitreal injection of bevacizumab.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">45</enrollment>
  <condition>Choroidal Neovascular Membrane</condition>
  <arm_group>
    <arm_group_label>Patients with choroidal neovascularization</arm_group_label>
    <description>CNV due to Age-Related Macular Degenerations and Myopia were included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrophysiology</intervention_name>
    <description>Visual Evoked Potential and Elctroretinogram</description>
    <arm_group_label>Patients with choroidal neovascularization</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Forty five eyes of 45 patients with choroidal neovascular membrane (CNV) who were prepared
        for intravitreal injections of 1.25mg bevacizumab underwent baseline ERG and VEP in both
        eyes before, and at 1 and 4 weeks after the intravitreal injections.Mean age was 50 years
        ranging from 24-62 years with 25 females, with 28 AMD and 17 myopic patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CNV

        Exclusion Criteria:

          -  Previous Intravitreal Injections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamer A macky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <state>--- Select One ---</state>
        <zip>11421</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20616681</url>
    <description>Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration.</description>
  </link>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>May 26, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>May 26, 2011</last_update_submitted>
  <last_update_submitted_qc>May 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tamer A Macky</name_title>
    <organization>Cario University</organization>
  </responsible_party>
  <keyword>Bevacizumab</keyword>
  <keyword>VEP</keyword>
  <keyword>ERG</keyword>
  <keyword>Optic nerve and retinal functions following intravitreal bevacizumab</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

